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The best hope for improved treatment of lung cancer lies in the development of effective new drugs. Lung cancer is the main cause of cancer related death in Britain, accounting for 17% of all new registered cases of cancer and 25% of cancer deaths.' Over 90% of patients with lung cancer die of their disease. Despite dramatic developments with cytotoxic chemotherapy for some malignancies over the last four decades, very little impact has been made on cure rate for patients with lung cancer. This is brought into perspective by comparing the change in five year survival rates of lung cancer and childhood acute lymphoblastic leukaemia over the last two decades. The five year survival rate for acute lymphoblastic leukaemia has increased from 8% to 70% as a result of improved treatment with cytotoxic drugs, whereas the five year survival rate for lung cancer for all ages remains unchanged at 8%, with over 40 000 deaths each year in the United Kingdom alone.
Prospects are bleak for all histological subtypes. Small cell lung cancer is very chemosensitive in its initial clinical stages; treatment with appropriate chemotherapy does improve survival, but only to around 10-15 months for patients with limited disease and to 7-11 months for those with extensive disease. Deaths from small cell lung cancer continue to occur beyond two years from diagnosis and a recent report gave a dismal five year survival rate of only 2.5%.2 For patients with non-small cell lung cancer surgery offers the best chance of cure, but by the time the diagnosis is made most patients have inoperable disease. The role of chemotherapy in the management of advanced non-small cell lung cancer is controversial. Modest response rates of 25-50% are achieved with combination chemotherapy containing cisplatin, but the response usually lasts only a few months and the survival benefit is marginal at most. 3 Most drugs in use today have been developed by empirical means with extensive screening processes. Many of the biochemical and pharmacological properties of a new drug are not determined until some time after the drug has achieved wide clinical application. Technological advances and a fuller understanding of the biology of cancer may allow us to identify specific molecular targets for which to design new drugs. An encouraging development is the characterisation of many of the receptors for autocrine and paracrine growth factors for small cell lung cancer and of the events occurring after activation of the receptors. Other possible drug targets include the DNA replicative machinery, the genes for tumour promoters and suppressors and the tumour cell cycle regulatory genes, and the transcripts and products of these genes. 
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group.bmj.com on August 28, 2017 -Published by http://thorax.bmj.com/ Downloaded from Camptotheca acuminata and, although it is active against experimental tumours, its clinical use is limited by severe haemorrhagic cystitis and low respone rates.'6 CPT11 is a potent inhibitor of topoisomerase I, has encouraging preclinical and antitumour activity, and in man is better tolerated than the parent compound. Phase I studies with single doses have shown that it has a maximum tolerated dose of 250 mg/m2, the dose limiting toxicity being myelosuppression. Other adverse reactions include alopecia and gastrointestinal toxicity but not haemorrhagic cystitis. ' phase specific drugs acting in the G2 phase of the cell cycle. Their efficacy depends on the schedule of administration. The response and survival of patients with small cell lung cancer is better when etoposide is given as repeated daily infusions of 100 mg/M2 for five days than as a single infusion of 500 mg/M2.2' The bioavailability of etoposide after oral administration is about 50%, which makes it a good candidate for repeated low dose oral administration. This has the potential advantages of easy administration and acceptable toxicity. 24 Ifosfamide also appears to be well suited to combination chemotherapy in the treatment of small cell lung cancer as it is less myelosuppressive than its parent compound, cyclophosphamide and is not cross resistant with standard alkylating agents, and its dose limiting toxicity, haemorrhagic cystitis, can be abrogated by Mesna without loss ofefficacy.25 It has activity as a single agent in patients previously treated with etoposide, vincristine, and doxorubicin,26 though response rates appear to be reduced ifprior treatment includes cyclophosphamide. 27 We reported a study at the Royal Marsden Hospital using ifosfamide in combination with carboplatin and etoposide, with a high response rate of 94% and a median survival of 19 months. 28 Drugs containing platinum, and in particular carboplatin, continue to play a prominent part in the management of small cell lung cancer. 29 The major dose limiting toxicity of carboplatin is myelosuppression, and it is therefore a good candidate for dose escalation studies in combination with haematopoietic growth factors, including interleukin-3. Several promising new platinum analogues are being developed, but their clinical efficacy in small cell lung cancer has still to be assessed.
Biological response modifiers represent a new modality in cancer treatment. Preliminary results are becoming available from studies in small cell lung cancer. A phase II trial of interleukin-2 in extensive disease is currently in progress.0 Previously untreated patients were initially given four cycles of doxorubicin, cyclophosphamide, etoposide, and platinum. Four weeks later all patients not achieving a complete response received a continuous infusion of interleukin-2 (4-5 x 106 mU/M2 a day) for four days repeated weekly for four weeks. Of the 67 patients, only 10 were treated with interleukin-2; three had an objective response, including two with complete remissions. Toxicity was severe enough to require discontinuation of treatment in at least 10% of patients. Dose limiting toxicity included hypotension, haemolysis, renal failure, hepatic dysfunction, and allergy. The long term role, if any, for interleukin-2 in the treatment of small cell lung cancer remains to be determined. The role of interferon-y as maintenance treatment is being evaluated in an EORTC trial in patients achieving a complete response to conventional chemotherapy. Ettinger" daunorubicin *All patients given induction chemotherapy followed by interleukin-2 for patients with assessable disease.
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evaluation of navelbine in combination with other drugs.
Zeniplatin is a water soluble, third generation platinum analogue active against murine tumour models and in human tumour xenografts. In preclinical studies it had a superior therapeutic dose ratio to that of cisplatin. We have given this drug to 29 previously untreated patients with advanced non-small cell lung cancer, six of whom achieved an objective response. In general, zeniplatin was well tolerated, apart from neutropenia, but one patient developed renal failure thought to be due to the drug. 33 At least three new antimetabolites have activity as single agents in non-small cell lung cancer. 10-EDAM (10-ethyl-5-deaza-aminopterin) is a methotrexate analogue that has a modification at the N-10 position and is a potent inhibitor of dihydrofolate reductase. It has better cellular uptake and polyglutamation and greater preclinical antitumour activity than methotrexate. Early-phase II New targets and future directions for the treatment of lung cancer New targets for treatment will, it is hoped, come from an increased understanding of the biology of tumour growth control. Several approaches are possible.
ONCOGENES AND ANTI-ONCOGENES
The proliferation rate of human lung cancer cell lines may be increased through overexpression of the myc family of proto-oncogenes. 43 Any stage in proto-oncogene expression could ultimately be a target for therapeutic intervention. The phorbol esters are agents that induce monocyte differentiation but they also decrease c-myc transcription, which results in slower growth rates in leukaemic cell lines. Possibly a similar approach could inhibit the growth of lung cancer in vitro and perhaps eventually in the clinic.
A fundamental and probably early event in most types of lung cancer is a deletion in chromosome 3, principally in the 3p [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Lung cancer, and in particular small cell lung cancer, is associated with the production of a series ofautocrine growth factors that stimulate malignant cell proliferation. These include bombesin like peptides, such as the mammalian homologue of bombesin, gastrin releasing peptide, insulin like growth factor I and transferrin (see second article in this series, December 1991, p924). Our group, for example, has shown that insulin like growth factor I is an autocrine growth factor in human small cell lung cancer and that in vitro tumour cell growth can be inhibited by monoclonal antibodies against insulin like growth factor I and its major receptor.47 This raises the possibility of antibody or oligopeptide analogue drugs directed against the receptor. Gastrin releasing peptide has also been shown to be an important growth factor for human small cell lung cancer.' We are currently investigating a group of 11-amino acid oligopeptide analogues of substance P, a sensory neurotransmitter, and looking at the effect of one on the growth of human small cell lung cancer xenografts. Some of these analogues are powerful inhibitors of human lung cancer growth in vitro and they are thought to act at least in part through inhibition of gastrin releasing peptide. Preliminary studies also show activity in xenografts. One agent might be subjected to clinical trial within the next two years.
HAEMATOPOIETIC GROWTH FACTORS
Several haematopoietic growth factors are now being used in the management of lung cancer and other malignancies to increase the rate of recovery from drug induced myelosuppression (see previous article in this series, p119). They should reduce treatment related toxicity and may enable larger doses of cytotoxic drugs to be given.' Neutrophil recovery can be accelerated in a dose and schedule dependent manner with granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor.'o Thrombocytopenia, however, is not affected by these agents. Newer haematopoietic growth factors, including interleukin-3, interleukin-1, and colony stimulating factor, have the potential for stimulating thrombopoiesis as well as granulopoiesis and may have a part to play in very high dose chemotherapy.
IMPROVING QUALITY OF LIFE
Despite its limited impact on survival, cytotoxic chemotherapy has a useful role in symptom relief.5' Efforts in this direction must be encouraged. Cachexia is often a distressing symptom in patients with cancer and attempts have been made to use drugs to improve nutrition. Medroxyprogesterone acetate has been evaluated by a double blind, randomised, placebo controlled trial in 41 patients with advanced cancer. The patients receiving medroxyprogesterone acetate had a significant improvement in appetite and in protein indicators ofnutrition-namely, serum thyroid binding prealbumin and retinol binding protein. The improvement was seen in patients with small cell lung cancer and in patients with other malignancies.52 In a similarly designed trial patients with unresectable non-small cell lung cancer receiving hydrazine sulphate had a higher energy intake and serum albumin concentration than the placebo group. The median duration of survival was 292 days in the group having hydrazine sulphate compared with 187 days in the placebo group but this difference was not statistically significant." Conclusion Prospects for conventional treatment of lung cancer remain poor. Developments in biology, however, suggest new targets for treatment. Current research must be designed in such a way as to allow useful drugs to be identified and ineffective drugs to be excluded in well designed clinical trials. The trials must allow new drugs to be tested as quickly as possible, early in the natural history of the disease, but at the same time they must give the patient the best chance of a good quality of life and the possibility of prolonged survival.
